Comparison of 2 Regimens that Include Interferon-α -2a plus Ribavirin for Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus--Coinfected Patients

Neau, Didier; Trimoulet, Pascale; Winnock, Maria; Rullier, Anne; Le Bail, Brigitte; Lacoste, Denis; Ragnaud, Jean-Marie; Bioulac-Sage, Paulette; lafon, Marie-Edith; Chêne, Geneviève; Dupon, Michel
June 2003
Clinical Infectious Diseases;6/15/2003, Vol. 36 Issue 12, p1564
Academic Journal
An open-label, randomized trial was conducted to compare the efficacy and safety of 2 regimens of interferon-α-2a (IFN-a-2a) plus ribavirin for management of chronic hepatitis C virus (HCV) infection in human immunodeficiency virus (HIV)-coinfected patients. Sixty-eight patients were randomized to receive IFN-α-2a at a dosage of either (1) 6 MU given 3 times per week for 24 weeks, followed by 3 MU 3 times per week for an additional 24 weeks (group A; 31 patients); or (2) 9 MU per day for 2 weeks, followed by 3 MU per day for 22 weeks, followed by 3 MU 3 times per week for 24 weeks (group B; 37 patients). Ribavirin was added at week 16 of therapy if HCV RNA remained detectable at week 12. Sustained virological response was achieved in 10 patients (15%; 6 in group A and 4 in group B). HCV genotypes 2 or 3 and a decrease in the HCV load of ≥3 log[SUB10] copies/mL between inclusion and week 4 were associated with virological response. In conclusion,) the combination of conventional IFN-α-2a and ribavirin has poor virological efficacy in HCV-HIV-coinfected patients.


Related Articles

  • Treatment of hepatitis C and anemia in human immunodeficiency virus-infected patients. Dieterich, Douglas T. // Journal of Infectious Diseases;5/16/2002 Supplement 2, Vol. 185, pS128 

    Because of shared modes of transmission, co-infection with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) is common. Co-infection with HIV increases HCV virus load, liver-related mortality, and the risk of sexual and perinatal transmission of HCV, and it may accelerate HCV...

  • Addition of Nitazoxanide to PEG-IFN and Ribavirin to Improve HCV Treatment Response in HIV-1 and HCV Genotype 1 Coinfected Persons Naïve to HCV Therapy: Results of the ACTG A5269 Trial. Amorosa, Valerianna K.; Luetkemeyer, Anne; Kang, Minhee; Johnson, Victoria A.; Umbleja, Triin; Haas, David W.; Yesmin, Suria; Bardin, Matthew C.; Chung, Ray T.; Alston-Smith, Beverly; Tebas, Pablo; Peters, Marion G. // HIV Clinical Trials (Thomas Land Publishers Incorporated);Nov/Dec2013, Vol. 14 Issue 6, p274 

    Background: We hypothesized that nitazoxanide (NTZ) added to pegylated interferon alfa-2a (PEG-IFN) and weight-based ribavirin (WBR) would improve hepatitis C virus (HCV) virologic responses in HCV treatment-naïve HIV-1/HCV genotype 1 coinfected persons. Methods: Prospective, single-arm study...

  • A 24-Week Treatment Strategy With Pegylated Interferon/Ribavirin in HIV/Hepatitis C Virus Genotype 3–Coinfected Patients Who Achieved a Rapid Virologic Response Results in a High Sustained Virologic Response Rate. Rivero-Juarez, Antonio; López-Cortés, Luis F.; Camacho, Angela; Mira, Jose A.; Téllez, Francisco; Marquez, Manuel; Merino, Dolores; Pineda, Juan A.; Rivero, Antonio // Clinical Infectious Diseases;Jan2014, Vol. 58 Issue 1, p130 

    We designed a study to evaluate the efficacy of a 24-week treatment strategy in HIV/hepatitis C virus (HCV) genotype 3–coinfected patients achieving rapid virologic response for a first HCV treatment with pegylated interferon plus ribavirin (peg-IFN/RBV). Our results suggest that a...

  • Genetic Variability of Hepatitis C Virus (HCV) 5’ Untranslated Region in HIV/HCV Coinfected Patients Treated with Pegylated Interferon and Ribavirin. Bukowska-Ośko, Iwona; Pawełczyk, Agnieszka; Perlejewski, Karol; Kubisa, Natalia; Caraballo Cortés, Kamila; Rosińska, Magdalena; Płoski, Rafał; Fic, Maria; Kaźmierczak, Justyna; Popiel, Marta; Ząbek, Piotr; Horban, Andrzej; Radkowski, Marek; Laskus, Tomasz // PLoS ONE;May2015, Vol. 10 Issue 5, p1 

    Association between hepatitis C virus (HCV) quasispecies and treatment outcome among patients with chronic hepatitis C has been the subject of many studies. However, these studies focused mainly on viral variable regions (E1 and E2) and usually did not include human immunodeficiency virus...

  • Modeling the Probability of Sustained Virological Response to Therapy with Pegylated Interferon plus Ribavirin in Patients Coinfected with Hepatitis C Virus and HIV. Medrano, Jose; Neukam, Karin; Rallón, Norma; Rivero, Antonio; Resino, Salvador; Naggie, Susanna; Caruz, Antonio; Calvino, Aida; Macías, Juan; Benito, Jose Miguel; Sánchez-Piedra, Carlos; Vispo, Eugenia; Barreiro, Pablo; McHutchison, John; Pineda, Juan Antonio; Soriano, Vincent // Clinical Infectious Diseases;11/15/2010, Vol. 51 Issue 10, p1209 

    Background. A single-nucleotide polymorphism (SNP) near the IL28B gene (rs12979860) strongly predicts sustained virological response to pegylated interferon plus ribavirin (pegIFN-RBV) treatment for chronic hepatitis C virus (HCV) infection. Given that therapy is poorly tolerated and rates of...

  • Top topics in HCV research arena. Puoti, Massimo; Rossotti, Roberto; Travi, Giovanna; Orso, Maurizio; Cristina Moioli, Maria // BMC Infectious Diseases;2012, Vol. 12 Issue Suppl 2, p1 

    A significant improvement in the rate of eradication of Hepatitis C Virus Genotype 1 has been achieved with the addition of Boceprevir and Telaprevir to pegylated interferon and ribavirin. These two drugs are the heralds of a new wave of antivirals that will improve the efficacy of pegylated...

  • Hepatology.  // Current Medical Literature: Gastroenterology;2010, Vol. 29 Issue 3, p73 

    The article summarizes several studies related to hepatology. One study examines the significance of twelve weeks posttreament follow-up to identifying the sustained virologic response of hepatitis C patients to pegylated interferon and ribavirin. Another study investigates the effectiveness of...

  • Benefit--risk assessment of new and emerging treatments for hepatitis C: focus on simeprevir and sofosbuvir. Gaetano, John N. // Drug, Healthcare & Patient Safety;2014, Vol. 6, p37 

    Greater understanding of the hepatitis C virus (HCV) genome and life cycle of the HCV virion allows for new targets for therapy that directly act on the viral machinery to inhibit replication. Numerous direct-acting antivirals are in development, and four have been brought to market. Simeprevir,...

  • Sustained Virologic Response to Peginterferon α-2a and Ribavirin in 335 Patients with Chronic Hepatitis C: A Tertiary Care Center Experience. Al Ashgar, Hamad; Khan, Mohammed Q.; Helmy, Ahmed; Al Swat, Khalid; Al Shehri, Abdullah; Al Kalbani, Abdalla; Peedikayel, Musthafa; Al Kahtani, Khalid; Al Quaiz, Mohammed; Rezeig, Mohammed; Kagevi, Ingvar; Al Fadda, Mohammed // Saudi Journal of Gastroenterology;Apr-Jun2008, Vol. 14 Issue 2, p58 

    Background/Aim: This retrospective study assessed the efficacy, safety, and the predictors of sustained viral response (SVR) to a 48-week-course of peginterferon α-2a (Pegasys) and ribavirin combination therapy in 335 consecutive Saudi patients with chronic hepatitis C virus (HCV) infection....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics